新型脑膜瘤治疗策略：免疫治疗和靶向治疗。
Novel Systemic Approaches for the Management of Meningiomas: Immunotherapy and Targeted Therapies.
机构信息
Center for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA.
Center for Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA; Department of Neurosurgery, Translational Neuro-Oncology Laboratory, Massachusetts General Hospital Cancer Center, Harvard Medical School.
出版信息
Neurosurg Clin N Am. 2023 Jul;34(3):447-454. doi: 10.1016/j.nec.2023.02.012. Epub 2023 Apr 4.
Meningiomas, the most prevalent primary intracranial tumor, arise from the arachnoid cap cells in the meninges, the membranes that surround the brain and the spinal cord. The field has long sought effective predictors of meningioma recurrence and malignant transformation, as well as therapeutic targets to guide intensified treatment such as early radiation or systemic therapy. Novel and more targeted approaches are currently being tested in numerous clinical trials for patients who have progressed after surgery and/or radiation. In this review, the authors discuss relevant molecular drivers that have therapeutic implications and examine recent clinical trial data evaluating targeted therapies and immunotherapies.
脑膜瘤是最常见的原发性颅内肿瘤，起源于脑膜中的蛛网膜帽细胞，脑膜是围绕大脑和脊髓的膜。该领域长期以来一直在寻求有效预测脑膜瘤复发和恶性转化的指标，以及治疗靶点，以指导强化治疗，如早期放疗或全身治疗。目前，针对手术后和/或放疗后进展的患者，正在进行大量临床试验来测试新的、更有针对性的方法。在这篇综述中，作者讨论了具有治疗意义的相关分子驱动因素，并研究了最近评估靶向治疗和免疫疗法的临床试验数据。
Zotero 插件